SCHEMBL30356557

SCHEMBL30356557

Oc1cc(C(F)(F)F)ccc1-c1nnc(N[C@@H]2CCCCC[C@H]2O)c2ccccc12

nearest known ligand 0.73

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 6/20 0.73
KCNH2 Q12809 1/20 0.73
IL1B P01584 7/20 0.46
TNF P01375 2/20 0.43
CHEK1 O14757 1/20 0.40
CHEK2 O96017 1/20 0.40
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TRPV3 Q8NET8 5/20 0.37
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29180710 1.00 NLRP3 (0.73) NLRP3KCNH2IL1BTNFCHEK1
SCHEMBL29180711 1.00 NLRP3 (0.73) NLRP3KCNH2IL1BTNFCHEK1
SCHEMBL29180709 1.00 NLRP3 (0.73) NLRP3KCNH2IL1BTNFCHEK1
SCHEMBL30771838 1.00 NLRP3 (0.73) NLRP3KCNH2IL1BTNFCHEK1
SCHEMBL30771809 1.00 NLRP3 (0.73) NLRP3KCNH2IL1BTNFCHEK1
SCHEMBL24855754 1.00 NLRP3 (0.73) NLRP3KCNH2IL1BTNFCHEK1
SCHEMBL24855439 0.99 NLRP3 (0.74) NLRP3KCNH2IL1BTNFCHEK1
SCHEMBL24855753 0.99 NLRP3 (0.74) NLRP3KCNH2IL1BTNFCHEK1
SCHEMBL24855438 0.99 NLRP3 (0.74) NLRP3KCNH2IL1BTNFCHEK1
SCHEMBL24855752 0.99 NLRP3 (0.74) NLRP3KCNH2IL1BTNFCHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503445-B2 Compounds and their use ASTRAZENECA AB (SE) 2025-12-23 US disclosed
US-20240383862-A1 COMPOUNDS AND THEIR USE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2024-11-21 US disclosed
US-11970463-B2 Compounds and their use ASTRAZENECA AB (SE) 2024-04-30 US disclosed
US-20230110122-A1 COMPOUNDS AND THEIR USE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230110122-A1 COMPOUNDS AND THEIR USE NLRP3, PYCARD, NLRP1 NLRP3 1/4885KCNH2 3499/4885IL1B 7/4885
US-20240383862-A1 COMPOUNDS AND THEIR USE NLRP3, PYCARD, NLRP1 NLRP3 1/4885KCNH2 3499/4885IL1B 7/4885
US-11970463-B2 Compounds and their use NLRP3, PYCARD, NLRP1 NLRP3 1/4885KCNH2 3499/4885IL1B 7/4885
US-12503445-B2 Compounds and their use NLRP3, PYCARD, NLRP1 NLRP3 1/4885KCNH2 3499/4885IL1B 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.